Boston Scientific Corp (BSX)vsGlaukos Corp (GKOS)
BSX
Boston Scientific Corp
$44.33
-2.50%
HEALTHCARE · Cap: $69.50B
GKOS
Glaukos Corp
$131.19
+2.72%
HEALTHCARE · Cap: $7.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 3639% more annual revenue ($20.61B vs $551.35M). BSX leads profitability with a 17.3% profit margin vs -34.3%. BSX appears more attractively valued with a PEG of 0.57. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
GKOS
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-18.7%
Fair Value
$37.36
Current Price
$44.33
$6.97 premium
Margin of Safety
-1.2%
Fair Value
$107.76
Current Price
$131.19
$23.43 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Revenue surging 41.2% year-over-year
Earnings expanding 1896.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
Expensive relative to growth rate
Trading at 11.4x book value
Weak financial health signals
ROE of -28.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : GKOS
The strongest argument for GKOS centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : GKOS
The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a mature stock while GKOS is a hypergrowth play — different risk/reward profiles.
GKOS carries more volatility with a beta of 0.81 — expect wider price swings.
GKOS is growing revenue faster at 41.2% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 44/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Glaukos Corp
HEALTHCARE · MEDICAL DEVICES · USA
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?